While palivizumab is effective in preventing severe RSV disease, it has its limitations. It is not a vaccine and does not provide long-term immunity. The protection it offers is temporary and requires monthly dosing during the RSV season. Additionally, it is not effective in treating an active RSV infection; it is purely a preventive measure.
